Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2010 - 2025)
Fennec Pharmaceuticals (FENC) posted Income from Continuing Operations of 4714000.0 for Q4 2025, down 656.66% on a QoQ basis from 623000.0 in Q3 2025, and down 214.06% year-over-year from 4133010.51 in Q4 2024.
Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 4714000.0 for Q4 2025.
- Quarterly Income from Continuing Operations fell 214.06% year-over-year to 4714000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 9656000.0 (down 5434.81% YoY) and the FY2025 annual result came in at 6207000.0, down 46.91% from the prior year.
- Income from Continuing Operations was 4714000.0 for Q4 2025 at Fennec Pharmaceuticals, down from 623000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12906000.0 in Q1 2024 and bottomed at 8050000.0 in Q3 2022.
- A 5-year average of 3298600.0 and a median of 4235500.0 in 2021 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 316.58% in 2024, while the deepest fall reached 222.47% in 2024.
- Fennec Pharmaceuticals' Income from Continuing Operations stood at 4256000.0 in 2021, then slumped by 58.04% to 6726000.0 in 2022, then soared by 61.08% to 2618000.0 in 2023, then jumped by 42.67% to 1501000.0 in 2024, then plunged by 214.06% to 4714000.0 in 2025.
- Business Quant data shows FENC's Income from Continuing Operations at 4714000.0 in Q4 2025, 623000.0 in Q3 2025, and 3155000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Fennec Pharmaceuticals | 346.75 Mn | 309.97 Mn | 12.01 Mn | -4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.71 Mn |
| Sep 30, 2025 | -623,000.00 |
| Jun 30, 2025 | -3.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | -5.71 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Mar 31, 2024 | 12.91 Mn |
| Dec 31, 2023 | -2.62 Mn |
| Sep 30, 2023 | -1.77 Mn |
| Jun 30, 2023 | -5.38 Mn |
| Mar 31, 2023 | -5.96 Mn |
| Dec 31, 2022 | -6.73 Mn |
| Sep 30, 2022 | -8.05 Mn |
| Jun 30, 2022 | -5.06 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.26 Mn |
| Sep 30, 2021 | -4.22 Mn |
| Jun 30, 2021 | -3.96 Mn |
| Mar 31, 2021 | -4.91 Mn |